Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for Loss of Share Certificates under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayStrides Pharma Science Ltd 2CINL24230MH1990PLC057062 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manjula Ramamurthy Designation: Company Secretary EmailId: manjula.r@strides.com Name of the Chief Financial Officer: Badree Komandur Designation: Executive Director Finance and Group CFO EmailId: badree.komandur@strides.com Date: 22/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Strides Pharma Science Ltd - 532531 - Certificate Pursuant To Regulation 40 (9) Of SEBI (LODR) Regulations, 2015
Pursuant to Regulation 40 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Compliance Certificate for the year ended on March 31, 2022, duly certified by the Practicing Company Secretary. Request you to kindly take the same on record. Strides Pharma Science Ltd - 532531 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 111120 Name of the Signatory :- Manjula RamamurthyDesignation :- Company Secretary and Compliance Officer Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 19, 2022 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment
Allotment of shares under Strides ESOP 2016 Plan Strides Pharma Science Ltd - 532531 - Compliance Certificate For The Year Ended 31.03.2022
As per the requirement of Regulation 7(3) of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we hereby confirm that the activities in relation to share transfer facility for the financial year April 1, 2021 to March 31, 2022 are maintained with the Company's Registrar and Share Transfer Agent, M/s. KFin Technologies Limited (Formerly, M/s. KFin Technologies Private Limited), Hyderabad who are registered with SEBI vide registration number INR000000221. Accordingly, the compliance in respect of Regulation 7(2) is ensured. Strides Pharma Science Ltd - 532531 - Disclosure of Voting results of EGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of EGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Strides Pharma Science Ltd - 532531 - Outcome Of The Extraordinary General Meeting Of The Company
Outcome of the Extraordinary General Meeting of the Company Strides Pharma Science Ltd - 532531 - Updated Proceedings Of The Extraordinary General Meeting (EGM) Of The Company
We wish to inform you that the EGM of the Company was held on Thursday, April 7, 2022 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the revised summary of proceedings of the EGM. This is for your information and records.